Listen Score
LS 27
Global Rank
TOP 10%

ABOUT THIS PODCAST 🔗

Update frequency:
weekly
Average audio length:
29 minutes
English
United States
12 episodes
since May 14, 2018
episodic

LATEST EPISODE 🔗

On this episode, I speak with Nick Lynch of the Pistoia Alliance ( www.pistoiaalliance.org ), a global nonprofit community of life science stakeholders that works to lower barriers to R&D innovation. A new area of strategic focus is artificial intelligence, which Nick oversees. On this episode,…

SEARCH PAST EPISODES

Search past episodes of Artificial Intelligence in Drug Discovery.

PREVIOUS EPISODES

On this episode, I speak with Lucas Siow, Head of Business Operations at ProteinQure ( www.proteinqure.com ). ProteinQure uses artificial intelligence and quantum computing to design protein-based drugs such as antibodies and peptides. On this episode, you'll learn the benefits of protein-based dru…
On this episode, I speak with Regina Barzilay of MIT's Machine Learning for Pharmaceutical Discovery and Synthesis consortium ( http://mlpds.mit.edu ). Regina is a prolific researcher with many highly cited papers in machine learning. On this episode, you'll learn what drove the need for the consor…
On this episode, I speak with Tim Guilliams and David Brown of Healx. Healx uses AI to repurpose existing drugs for rare diseases. They claim their approach can bring new treatments to patients 80% faster and 90% cheaper. On this episode, you’ll learn how rare diseases are surprisingly common, why …
On this episode, I speak with John Cassidy, CEO of Cambridge Cancer Genomics ( www.ccg.ai ). CCG aims to transform oncology by combining liquid biopsy with genomics and artificial intelligence to predict disease progression and improve treatment. On this episode, you’ll learn about the challenges w…
On this episode, I speak with Kristen Fortney, founder and CEO of BioAge Labs ( www.bioagelabs.com ). Kristen leads one of just a few companies focused explicitly on aging itself, rather than the diseases for which aging puts people at greater risk. In this episode, you’ll learn how BioAge combines…
On this episode, I speak with Sam Cooper, cofounder and CEO of Phenomic AI ( www.phenomic.ai ). Sam and his team use machine learning for automated image analysis to study cell biology and screen drugs. But that’s just the beginning. In this episode, you’ll learn about Phenomic’s distinct approach …
On this episode, I speak with Shai Shen-Orr, cofounder and chief scientist of CytoReason ( www.cytoreason.com ). CytoReason has created a machine learning model of the immune system. This model can integrate data from multiple sources to support drug discovery, the creation of diagnostic tools, and…
On this episode, I speak with Leila Pirhaji, founder and CEO of ReviveMed ( www.revive-med.com ). ReviveMed uses artificial intelligence to unlock the therapeutic potential of metabolomics. Before learning about ReviveMed, I knew little about metabolomics. Leila is an articulate and enthusiastic te…
On this episode, I speak with Mostapha Benhenda of Startcrowd ( http://www.startcrowd.club ). In January, Mostapha wrote a controversial article critiquing several research labs ( https://bit.ly/2qINvQ9 ). Some accused him of using the article just to promote his service. Others agreed with his cri…
Disclaimer: The podcast and artwork embedded on this page are from Simon Smith, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.